Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Pembrolizumab/Anlotinib Combo Has Efficacy in Refractory or Platinum-Resistant Recurrent High-Grade Serous Ovarian Cancer

September 8th 2022

Pembrolizumab monotherapy and in combination with anlotinib demonstrated encouraging efficacy and safety when administered to patients with refractory or platinum-resistant recurrent high-grade serous ovarian cancer.

Taking Action to Individualize Ovarian Cancer Care: Key Takeaways

September 7th 2022

In this fifth episode of OncChats: Taking Action to Individualize Ovarian Cancer Care, John Nakayama, MD, and Christopher Morse, MD, share key takeaways from their discussion on how to best individualize care for patients with ovarian cancer.

Taking Action to Individualize Ovarian Cancer Care: Excitement Surrounding PARP Inhibition

August 31st 2022

In this fourth episode of OncChats: Taking Action to Individualize Ovarian Cancer Care, John Nakayama, MD, and Christopher Morse, MD, discuss key developments made with PARP inhibitors in the ovarian cancer treatment paradigm.

Taking Action to Individualize Ovarian Cancer Care: Somatic Vs Germline Testing

August 24th 2022

In this third episode of OncChats: Taking Action to Individualize Ovarian Cancer Care, John Nakayama, MD, and Christopher Morse, MD, explain the differences between germline and somatic testing in patients with ovarian cancer.

Taking Action to Individualize Ovarian Cancer Care: Counseling Those with BRCA Mutations

August 17th 2022

In this second episode of OncChats: Taking Action to Individualize Ovarian Cancer Care, John Nakayama, MD, and Christopher Morse, MD, discuss how to counsel patients with ovarian cancer whose tumors harbor BRCA mutations.

Taking Action to Individualize Ovarian Cancer Care: Effect of BRCA on Treatment

August 10th 2022

In this first episode of OncChats: Taking Action to Individualize Ovarian Cancer Care, John Nakayama, MD, and Christopher Morse, MD, discuss how BRCA mutational status affects treatment decisions for patients with ovarian cancer.

Niraparib Maintenance Prolongs PFS in Newly Diagnosed Advanced Ovarian Cancer After Response to Chemotherapy

July 26th 2022

Maintenance therapy with niraparib significantly improved progression-free survival compared with placebo in Chinese patients with newly diagnosed advanced ovarian cancer who achieved a complete response or partial response to first-line chemotherapy.

CHMP Recommends Restricting Third-Line Rucaparib Use in BRCA+ Ovarian Cancer

July 25th 2022

The European Medicines Agency Committee for Medicinal Products for Human Use has recommended that rucaparib no longer be used as monotherapy for the third-line treatment of patients with platinum-sensitive, relapsed or progressive BRCA-mutated high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Ofranergene Obadenovec/Paclitaxel Combo Misses Survival End Points in Platinum-Resistant Ovarian Cancer

July 20th 2022

The combination of ofranergene obadenovec and paclitaxel failed to elicit a statistically significant improvement in progression-free survival or overall survival compared with paclitaxel alone in patients with platinum-resistant ovarian cancer, missing the coprimary end points of the OVAL trial.

Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer

July 18th 2022

Dr Monk discusses pertinent efficacy and safety data from the ATHENA-MONO trial, which evaluated first-line maintenance treatment with rucaparib in patients with stage III-IV high-grade ovarian cancer.

Mirvetuximab Soravtansine Displays Promising Efficacy in Platinum-Resistant Ovarian Cancer

July 2nd 2022

Patients with platinum-resistant ovarian cancer have historically been an underserved population with few effective treatment options.

Niraparib Plus Dostarlimab Misses the Mark in Platinum-Resistant Ovarian Cancer

June 25th 2022

The combination of niraparib and dostarlimab produced a low overall response rate in patients with platinum-resistant ovarian cancer without a known BRCA mutation who had progressed and received prior bevacizumab, one that did not reach the threshold for second-stage accrual to the phase 2 MOONSTONE/GOG-3032 trial.

Farletuzumab Ecteribulin Shows Early Activity in Platinum-Resistant Ovarian Cancer

June 21st 2022

The antibody-drug conjugate farletuzumab ecteribulin demonstrated notable antitumor activity with a manageable safety profile in patients with platinum-resistant ovarian cancer.

Rucaparib Maintenance Shows PFS Benefit in Ovarian Cancer, Independent of HRD Status

June 6th 2022

Rucaparib elicited a significant improvement in progression-free survival outcomes vs placebo as first-line maintenance therapy in patients with ovarian cancer who responded to first-line platinum-based chemotherapy across patient subgroups.

Ruxolitinib Plus Chemo as Pre/Postsurgical Treatment Prolongs PFS in Ovarian Cancer

June 6th 2022

Twice-daily oral ruxolitinib plus carboplatin and paclitaxel given as frontline neoadjuvant and post-surgical treatment to patients with stage III or IV ovarian cancer was found to be feasible and to improve progression-free survival compared with chemotherapy alone.

Galinpepimut-S Plus Pembrolizumab Displays Early Efficacy in WT1+ Ovarian Cancer

May 31st 2022

Galinpepimut-S in combination with the PD-1 inhibitor pembrolizumab elicited a clinical benefit in patients with Wilms’ tumor-1-positive relapsed/refractory platinum-resistant advanced metastatic ovarian cancer, according to top line-line data from a phase 1/2 trial (NCT03761914).

The Saga of Regional Therapy in the Treatment of Ovarian Cancer

May 17th 2022

Despite numerous well-designed and conducted randomized trials, a definitive answer to the role of specific disease management remains unclear, particularly in the discussions of the optimal role for the regional delivery of cytotoxic chemotherapy in the treatment of patients with ovarian cancer.

Navicixizumab/Paclitaxel Combo Demonstrates Early Promise in Platinum-Resistant Ovarian Cancer

May 13th 2022

The addition of navicixizumab to paclitaxel produced encouraging responses with manageable toxicity in patients with platinum-resistant ovarian cancer irrespective of prior treatment with bevacizumab.

Novel FSHR-Mediated CAR T Approach Under Exploration in Recurrent Ovarian Cancer

April 28th 2022

An investigative follicle-stimulating hormone receptor–mediated CAR T-cell technology is under exploration in patients with recurrent ovarian cancer.

FDA Grants Fast Track Designation to VB-111 for Platinum-Resistant Ovarian Cancer

April 27th 2022

The FDA has granted a fast track designation to VB-111, a targeted anticancer viral gene therapy, for use as a potential therapeutic option in patients with platinum-resistant ovarian cancer.